Physician profile
Nitin Vasant Sheth
NPI 1184737611
$542.14
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $54.26 · 2021: $94.22 · 2022: $115 · 2024: $17.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $94.16 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $79.27 | 2019-2022 | |
| Abbvie INC. | $62.83 | 2021 | |
| Janssen Pharmaceuticals, INC | $49.30 | 2019-2022 | |
| Lundbeck LLC | $48.51 | 2019-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $45.80 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $34.87 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.78 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.39 | 2021 | |
| Shire North American Group INC | $13.89 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.88 | 2022 | |
| Merck Sharp & Dohme LLC | $12.29 | 2022 | |
| Indivior INC. | $11.99 | 2019 | |
| Neurocrine Biosciences, INC. | $11.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.